ATE471722T1 - Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen - Google Patents

Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen

Info

Publication number
ATE471722T1
ATE471722T1 AT04720472T AT04720472T ATE471722T1 AT E471722 T1 ATE471722 T1 AT E471722T1 AT 04720472 T AT04720472 T AT 04720472T AT 04720472 T AT04720472 T AT 04720472T AT E471722 T1 ATE471722 T1 AT E471722T1
Authority
AT
Austria
Prior art keywords
compositions
apelin
angiogenesis
regulating angiogenesis
methods
Prior art date
Application number
AT04720472T
Other languages
English (en)
Inventor
Paul Krieg
Original Assignee
Univ Arizona State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona State filed Critical Univ Arizona State
Application granted granted Critical
Publication of ATE471722T1 publication Critical patent/ATE471722T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT04720472T 2003-03-12 2004-03-12 Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen ATE471722T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45403403P 2003-03-12 2003-03-12
US52815503P 2003-12-09 2003-12-09
PCT/US2004/007738 WO2004081198A2 (en) 2003-03-12 2004-03-12 Methods for modulating angiogenesis with apelin compositions

Publications (1)

Publication Number Publication Date
ATE471722T1 true ATE471722T1 (de) 2010-07-15

Family

ID=32994538

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04720472T ATE471722T1 (de) 2003-03-12 2004-03-12 Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen

Country Status (6)

Country Link
US (1) US7736646B2 (de)
EP (1) EP1613348B1 (de)
JP (1) JP2006523209A (de)
AT (1) ATE471722T1 (de)
DE (1) DE602004027798D1 (de)
WO (1) WO2004081198A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019193A1 (ja) * 2004-08-20 2006-02-23 Takeda Pharmaceutical Company Limited 阻害剤・促進剤の用途
JP2008013436A (ja) * 2004-10-14 2008-01-24 Kanazawa Univ 血管形成促進剤
WO2006076736A2 (en) * 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US20080026986A1 (en) * 2006-06-05 2008-01-31 Rong-Fu Wang Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
CA2669260C (en) * 2006-11-09 2019-01-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
AU2008297885A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of GLP-1 as a therapeutic agent
WO2009033819A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20120277144A1 (en) * 2009-11-04 2012-11-01 Henricus Johannes Duckers Novel compounds for modulating neovascularisation and methods of treatment using these compounds
SI3045183T1 (sl) * 2011-03-11 2018-11-30 Genzyme Corporation Pegiliran Apelin in njegove uporabe
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
KR101327663B1 (ko) 2011-10-07 2013-11-14 중앙대학교 산학협력단 안지오제닌의 신규 용도
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2014152955A1 (en) 2013-03-14 2014-09-25 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
WO2015077491A1 (en) * 2013-11-20 2015-05-28 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
US11104730B2 (en) * 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
WO2015140296A2 (en) * 2014-03-20 2015-09-24 Centre National De La Recherche Scientifique (Cnrs) Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer
JOP20160211B1 (ar) 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CN118078956A (zh) * 2016-05-06 2024-05-28 免疫新炉有限公司 用于受控和持续释放的elp融合蛋白
AU2018266324B2 (en) 2017-05-06 2024-02-01 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
GB201805675D0 (en) 2018-04-05 2018-05-23 Davenport Anthony Peter Compounds For Use As Apelin Receptor Antagonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5496698A (en) 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
AU4190893A (en) * 1992-07-17 1994-01-20 Suntory Limited Megakaryocyte differentiation factor
AU1685499A (en) * 1997-12-24 1999-07-19 Takeda Chemical Industries Ltd. Polypeptide, their production and use
JP4429410B2 (ja) * 1997-12-24 2010-03-10 武田薬品工業株式会社 新規生理活性物質、その製造法および用途
EP1138772A4 (de) * 1998-12-11 2005-04-06 Takeda Chemical Industries Ltd Verfahren zur herstellung von apelin
HRP20010821A2 (en) 1999-05-06 2002-12-31 Pfizer Prod Inc Substituted benzolactam compounds
WO2000068244A1 (en) * 1999-05-12 2000-11-16 Smithkline Beecham Corporation 7tm receptor mouse apj
US20040033495A1 (en) * 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2006076736A2 (en) * 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
CA2669260C (en) * 2006-11-09 2019-01-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis

Also Published As

Publication number Publication date
JP2006523209A (ja) 2006-10-12
US7736646B2 (en) 2010-06-15
WO2004081198A3 (en) 2004-12-16
EP1613348A2 (de) 2006-01-11
WO2004081198A2 (en) 2004-09-23
DE602004027798D1 (de) 2010-08-05
EP1613348B1 (de) 2010-06-23
EP1613348A4 (de) 2006-07-05
US20040219152A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
DE602004027798D1 (de) Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
WO2006023893A3 (en) Methods for modulating angiogenesis and apoptosis with apelin compositions
ATE454161T1 (de) Verwendung von fviia oder fviiai zur behandlung von endothelialer fehlfunktion bzw zur inhibierung der angiogenese
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
ATE554087T1 (de) Neue kinaseinhibitoren
ATE369144T1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
WO2005005462A3 (en) Blys antagonists and uses thereof
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
EA200600440A1 (ru) 4-((феноксиалкил)тио)еноксиуксусные кислоты и их аналоги
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
WO2006076736A3 (en) Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
BR0315689A (pt) Alvo para terapia de dano cognitivo
ATE311388T1 (de) Pyrimidotriazine als phosphataseinhibitoren
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE366572T1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
ATE376419T1 (de) Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
ATE506370T1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
ATE506073T1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties